TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
29 hedge funds and large institutions have $1.39M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
54% more capital invested
Capital invested by funds: $903K → $1.39M (+$487K)
21% more funds holding
Funds holding: 24 → 29 (+5)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$108K |
| 2 |
Renaissance Technologies
New York
|
+$48.3K |
| 3 |
Jane Street
New York
|
+$43.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$21.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$484K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$45.3K |
| 3 |
Millennium Management
New York
|
-$27.9K |
| 4 |
Squarepoint
New York
|
-$5.56K |
| 5 |
GS
GTS Securities
New York
|
-$2.76K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GPFA
26
Game Plan Financial Advisors
Westlake,
Ohio
| $430 | – | – | – |
|
|
TC
27
Truvestments Capital
Sarasota,
Florida
| $137 | – | – | – |
|
28
Wells Fargo
San Francisco,
California
| $89 | – | – | – |
|
|
IC
29
Ikarian Capital
Dallas,
Texas
| – | -$484K | -138,277 | Closed |
|
|
BFM
30
Boothbay Fund Management
New York
| – | -$45.3K | -12,942 | Closed |
|
|
GS
31
GTS Securities
New York
| – | -$2.76K | -790 | Closed |
|
32
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$140 | -40 | Closed |
|
33
Morgan Stanley
New York
| – | -$70 | -20 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$24 | -5 | -38% |
|
TCON Hedge Fund Activity: Q1 2024 in Review
29 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2024, worth a combined $1.39M — up 54% from $903K a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TCON positions and 6 closed out — a net gain of 5 holders — while 2 added to existing stakes and 5 trimmed.
The largest buyer was LPL Financial, opening a new position worth an estimated $108K. The largest seller was Ikarian Capital, exiting entirely with an estimated $484K sold.
- 29 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2024, up from 24 in Q4 2023.
- Funds reported $1.39M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2024, up 54% quarter-over-quarter.
- 11 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2024 and 6 closed out, a net change of +5 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2024 was LPL Financial, an estimated $108K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2024 was Ikarian Capital, an estimated $484K sold.
Based on aggregated 13F filings for Q1 2024.